A1APU

A1APU
Identifiers
	IUPAC name (2S)-3-(3-methoxy-4-methylphenyl)-N-methyl-2-[[2-[1-(5-phenylmethoxypyridin-3-yl)naphthalen-2-yl]sulfanylacetyl]amino]propanamide;
PubChem CID	171642066;
ChemSpider	129393366;
Chemical and physical data
Formula	C36H35N3O4S
Molar mass	605.75 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=C(C=C1)C[C@@H](C(=O)NC)NC(=O)CSC2=C(C3=CC=CC=C3C=C2)C4=CC(=CN=C4)OCC5=CC=CC=C5)OC;
	InChI InChI=1S/C36H35N3O4S/c1-24-13-14-26(18-32(24)42-3)17-31(36(41)37-2)39-34(40)23-44-33-16-15-27-11-7-8-12-30(27)35(33)28-19-29(21-38-20-28)43-22-25-9-5-4-6-10-25/h4-16,18-21,31H,17,22-23H2,1-3H3,(H,37,41)(H,39,40)/t31-/m0/s1; Key:IBQRWMDLUKSOJL-HKBQPEDESA-N;

A1APU (10105-368-30-605-0) is a negative allosteric modulator (NAM) of the μ-opioid receptor (MOR) which has been developed as a potential treatment for opioid overdose. In animal studies it increases the potency and effective duration of naloxone making it able to block opioid-induced respiratory depression at a tenth of the normal dose.^[1]^[2]

References

^ O'Brien ES, Rangari VA, El Daibani A, Eans SO, Hammond HR, White E, et al. (July 2024). "A µ-opioid receptor modulator that works cooperatively with naloxone". Nature. 631 (8021): 686–693. Bibcode:2024Natur.631..686O. doi:10.1038/s41586-024-07587-7. PMC 11998091. PMID 38961287.
^ WO 2024/112721, O'Brian E, Kumar KK, Kobilka B, "Allosteric Modulators of the μ-Opioid Receptor and Cannabinoid receptor 1", published 2024-05-30, assigned to Cz Biohub Sf, Llc and The Board Of Trustees Of The Leland Stanford Junior University